Gilead has claimed in its legal suit that claims made by pharma giants Merck and AbbVie on Sovaldi are patently wrong.
Gilead Sciences entered into the market with an interferon-free oral hepatitis C fighter. It is expected that this category would hit $20 billion in sales by 2020. The company's Sovaldi has been racking up unprecedented sales and is also attracting several legal suit.
Also read: GE Cuts Full-Year Sales Forecast